iMediSync
iMediSync is a Seoul, South Korea-based digital mental health company that builds AI-powered dry-electrode EEG headsets (iSyncWave, iSyncMe) and cloud QEEG analytics (iSyncBrain, iSyncHeart) for hospitals, dementia centers, government health programs, and research institutions across 9+ countries.
- Company typePrivate
- Founded2012
- HeadquartersYeoksamdong, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What iMediSync does
iMediSync (주식회사 아이메디신) is a Seoul, South Korea-based digital mental health company founded in 2012 by Seung Wan Kang (MD, PhD) that develops an integrated AI platform for brainwave-based screening and therapy. The system pairs dry-electrode wireless EEG headsets (iSyncWave, FDA 510(k) cleared; iSyncMe, 2023 entry-level variant) with a cloud-based AI analytics platform (iSyncBrain, FDA 510(k) Class II cleared) and an HRV-based cardiac analytics add-on (iSyncHeart). The proprietary stack rests on a sex- and age-differentiated EEG normative database built since 2013 in collaboration with Seoul National University, AI-automated denoising, sLORETA 3D source-level mapping, and clinically validated biomarkers for amnestic MCI (90.9% accuracy in a 442-dataset multi-site trial), Alzheimer's, Parkinson's, depression, stroke cognitive impairment, coma prognosis, Lewy body dementia, and pediatric ADHD. Devices integrate 850 nm near-infrared photobiomodulation therapy alongside 19-channel EEG plus PPG for HRV, enabling a sub-10-minute brain health scan.
The company generates revenue across four streams: hardware device sales (iSyncWave, iSyncMe) to hospitals and clinics, recurring SaaS subscriptions for iSyncBrain/iSyncHeart cloud analytics, software medical device licensing for FDA/KFDA-cleared products, and paid professional training (QEEG courses priced at KRW 100,000 per session, NeuroBridge 2025 Asia-Pacific workshop at USD 700). Pricing for hardware and SaaS is handled through direct sales quotation rather than public disclosure.
Customer base spans 60+ institutional users within six months of iSyncWave launch, 25+ Korean hospital partnerships (Seoul Asan, Seoul National University Bundang, Yonsei Severance, Boramae, Chung-Ang, etc.), government health programs (Gwangju AI ecosystem, Busan mobile medical checkup via Busan National University Hospital, Korea Public Procurement Service innovative prototype designation), pediatric education partnerships (KidsScholar), and research deployments (KAIST, Mila/Quebec AI Institute). International expansion is executed through authorized regional distributors in the US (Arcadia, CA subsidiary), Australia, Japan (jMediSync), Thailand, Taiwan, and Romania/Europe (Neuros Europe SRL), with Dubai/Middle East exploration via Myungra Co. The Lotte Healthcare/Cazzle partnership adds a consumer wellness distribution channel.
iMediSync firmographics
Firmographics- Name
- iMediSync
- Legal name
- 주식회사 아이메디신 (iMediSync Co., Ltd.)
- Website
- https://imedisync.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- iMediSync is a Seoul, South Korea-based digital mental health company that builds AI-powered dry-electrode EEG headsets (iSyncWave, iSyncMe) and cloud QEEG analytics (iSyncBrain, iSyncHeart) for hospitals, dementia centers, government health programs, and research institutions across 9+ countries.
- Ownership category
- akta.pro rank
iMediSync industry classification
Industry- Product category
- Digital Mental Health Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182), Medical and Diagnostic Laboratories (62151)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD), Wearables & Consumer IoT Integration Platforms (BYOD) (HLACAFAF), Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO), Neurology Telemedicine Platforms (HLALAGAC)
Keywords
Where iMediSync is headquartered
LocationHeadquarters
- HQ city
- Yeoksamdong
- HQ country
- South Korea
- HQ region
- Asia
Offices7 records
Markets served
iMediSync business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Hardware Device Sales (iSyncWave, iSyncMe): Sale of wireless dry EEG headset devices — iSyncWave (helmet form, weight 1600g) and iSyncMe (lighter entry model, 1200g). Both integrate EEG measurement with PBM LED therapy. Sold to hospitals, clinics, and government health programs directly and through distributors.
- Cloud-Based AI Analytics Platform (iSyncBrain, iSyncHeart): SaaS subscription model for cloud-hosted QEEG and HRV analysis. iSyncBrain-C (clinical series), iSyncBrain-M (medical series for MCI), and iSyncBrain-R (research series) offered as software medical devices. Users access automated reports, brain mapping, and disease biomarkers via web/App.
- Software Medical Device Licensing: Sales and distribution of FDA 510(k) and KFDA-cleared software medical devices — iSyncBrain-C (FDA K222838) and iSyncBrain-M1 (MCI Classifier). Licensed to medical institutions for clinical use in dementia early screening and brain health assessment.
- Professional Services and Training: Paid QEEG training programs for medical professionals — basic and advanced courses offered at 100,000 KRW per session. Educational workshops including NeuroBridge 2025 (Asia-Pacific, $700 USD registration fee).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One-time | QEEG Basic Training for Physicians |
| Other | One-time | QEEG Advanced Training for Physicians |
| Other | One-time | NeuroBridge 2025 Asia-Pacific Workshop |
| Subscription | Annual | iSyncBrain Cloud Analytics SaaS |
| Unit Pricing | One-time | iSyncWave and iSyncMe Hardware Devices |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
iMediSync product offering
Product offeringCore offering
iMediSync develops and sells wireless dry-electrode EEG headsets (iSyncWave and iSyncMe) integrated with near-infrared photobiomodulation (PBM) therapy, connected to a cloud-based AI analytics platform (iSyncBrain for QEEG analysis, iSyncHeart for HRV analysis). The platform performs automated brain health screening, age- and sex-normed comparison, and AI-based disease biomarker detection for conditions such as Alzheimer's, amnestic mild cognitive impairment, Parkinson's, depression, and stroke cognitive impairment. The offering is sold as regulated medical device hardware plus SaaS analytics subscriptions to hospitals, clinics, government health programs, and wellness/senior care operators.
Product overview
iMediSync offers an integrated AI digital mental healthcare platform consisting of hardware devices and cloud-based software. The portfolio centers on iSyncWave and iSyncMe wearable EEG headsets with integrated photobiomodulation (PBM) therapy, which connect to the iSyncBrain cloud analytics platform for AI-powered brain health assessment. iSyncBrain provides multiple product lines (M for medical/dementia screening, C for clinical norm comparison, R for research) while iSyncHeart extends the platform to cardiac autonomic analysis via HRV. Together, the platform enables 10-minute brain health screening with automated QEEG analysis, disease biomarker detection (aMCI, Alzheimer's, depression), and guided digital therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- iSyncWave: Wireless dry EEG measurement and therapy device with integrated EEG scanning and near-infrared photobiomodulation (PBM) capabilities. FDA 510K cleared Class 2 medical device.
- iSyncBrain
- iSyncHeart
- iSyncMe
Products and services
- iSyncWave Wireless dry-type EEG measurement headset with integrated near-infrared photobiomodulation (PBM) therapy. Features 19-channel dry EEG with automatic International 10/20 positioning, PPG sensor for HRV measurement, and 850nm NIR-LED therapy. Enables 10-minute brain health measurement and analysis cycle without gel electrodes. FDA 510(k) cleared (K220056) and KFDA Class 2 medical device. Sold to hospitals, clinics, dementia centers, and government health programs for neurological screening and digital therapeutics.
- iSyncMe Lightweight wireless dry-electrode EEG headset with integrated photobiomodulation (PBM) therapy, positioned as a next-generation entry-level device. Features improved signal quality accuracy, lighter weight (1200g), enhanced PBM performance, flexible auto-fit banding for all head sizes (41.5cm to 64.2cm), and remote mental care capability. Combines 19-channel dry EEG with 850nm NIR-LED photobiomodulation.
- iSyncBrain Cloud-based AI EEG analytics platform offered in three series: iSyncBrain-M (Medical) for dementia early detection and amnestic MCI screening with disease biomarkers; iSyncBrain-C (Clinical) for healthy norm comparisons at sensor and source levels; iSyncBrain-R (Research) for group statistics and placebo-controlled studies. Features AI-automated denoising, 3D brain mapping (sLORETA), and AI-based biomarker reports compared against the world's first sex- and age-differentiated EEG normative database. FDA 510(k) cleared (K222838) and KFDA software medical device. Delivered via SaaS subscription on web and Android app.
- iSyncHeart HRV-based machine learning biomarker solution for depression/anxiety detection and stress profiling. Provides automated HRV extraction and standardization, emotion analysis, sympathovagal balance assessment, and GAS (General Adaptation Syndrome) phase stress analysis based on heart rate variability norms. KFDA-registered medical device. Used across clinical fields including psychiatry, cardiology, and wellness programs.
Quantifiable outcome
- Amnestic MCI detection accuracy of 90.9% (sensitivity 93.2%, specificity 90.2%) in multi-site clinical trial with 442 EEG datasets
- +3 more outcomes
Companies that use iMediSync
Customer profileSegments5 records
Ideal customer profiles4 records
iMediSync technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
iMediSync partnerships and signals
Strategic signalPartnerships
35 partnerships are on record, tiered key, core and minor.
- Gwangju Metropolitan CitykeyMOU as part of Gwangju's AI industry ecosystem initiative (175th–182nd partnership). iMediSync to establish a regional office in Gwangju for AI mental healthcare technology development. Collaboration on talent cultivation, job creation, and AI industry ecosystem support leveraging Gwangju's National AI Data Center infrastructure.
- Lotte HealthcarecoreMOU for joint development of AI-based healthcare business models in wellness and senior care. Lotte Healthcare's personalized health management platform 'Cazzle' will integrate iMediSync's brainwave measurement services. Long-term branding and marketing cooperation planned alongside technology development.
- KidsScholarkeyMOU for mutual collaboration in early childhood education and brain health. Planned services include brainwave measurement for KidsScholar VIP customers, integration of brain analysis with reading effectiveness evaluation, joint marketing, and service pilot programs for child development applications.
- Mila (Quebec AI Institute)corePartnership with Mila, the world's largest academic deep learning research institute founded by Professor Yoshua Bengio, to advance AI-driven mental healthcare. The collaboration aims to develop cutting-edge solutions for detecting and addressing brain dysfunctions, combining Mila's AI research prowess with iMediSync's EEG-based digital mental health platform.
- Busan Metropolitan City / Busan National University HospitalkeyiSyncWave introduced to Busan City's visiting mobile medical checkup system ('door-to-door health service'). Implemented at Busan National University Hospital's medical bus equipped with portable ultrasound, X-ray, and EEG. First nationwide implementation of EEG in mobile health screening.
- Seoul Asan Hospital (서울아산병원)keyJoint research MOU for developing digital diagnosis and treatment methods for Parkinson's disease. Research collaboration using QEEG biomarkers for Parkinson's pathology detection and digital therapeutic monitoring.
- Seoul National University Hospital (서울대병원)keyResearch collaboration for brain stroke treatment studies using iSyncBrain EEG analysis technology. Joint development of digital biomarkers for stroke rehabilitation prognosis and cognitive impairment prediction.
- iMediSync North America Inc.keyUS subsidiary and authorized distributor for North America. Contact: [email protected], +1-480-229-0054. Office located in Arcadia, California. Handles US sales, distribution, and customer support for the North American market.
- iMediSync Australia Inc.keyAuthorized distributor for Australia and potentially broader Oceania. Located in Tweed Heads, NSW. Contact: [email protected]. Website: imedisyncaustralasia.com.au.
- jMediSync Inc.keyAuthorized distributor for Japan. Located in Minato-ku, Tokyo. Contact: [email protected], +81-3-3593-5270. Serving the Japanese healthcare market with iMediSync products.
- IMEDISYNC(THAILAND) Co., Ltd.keyAuthorized distributor for Thailand. Located in Bangkok. Contact: [email protected], +66-2-276-4388. Distributing iMediSync EEG and mental health solutions in the Thai market.
- Chun International Co. LTD.keyAuthorized distributor for Taiwan. Located in New Taipei City. Contact: [email protected]. Distributing iMediSync products in the Taiwan market.
- Neuros Europe SRLcoreExclusive distributor for Romania and broader Europe, led by CEO Diana Palotos who surpassed annual sales targets in the first 12 months of partnership (2025). Contact: [email protected], +40 744 134510. Websites: neuros.ro and imedisync-neuros.com/en. Successfully driving European market expansion.
- KAIST (Korea Advanced Institute of Science and Technology)keyMOU signed with KAIST President Lee Guang-hee for brain disease prevention research collaboration. Academic partnership leveraging KAIST's neuroscience and AI research capabilities for digital mental healthcare development.
- Seoul St. Mary's Hospital, The Catholic University of KoreakeyMOU for academic exchange and joint research in brain neural network studies. Collaboration on developing biomarkers and clinical applications using iSyncBrain's standardized QEEG analysis platform.
- Seoul National University Boramae Medical CenterkeyResearch collaboration MOU for developing EEG-based biomarkers and clinical applications. Partnership for early detection of dementia and neurodegenerative diseases using iSyncBrain QEEG analysis platform.
- Chung-Ang University HospitalkeyClinical trial site for amnestic MCI EEG biomarker validation. 103 aMCI and 339 normal control EEG datasets collected and analyzed using iSyncBrain. Key clinical validation partner for regulatory submissions to KFDA.
- Seoul National University Bundang HospitalkeyClinical trial site for aMCI EEG biomarker development. Partnership for validation of QEEG-based mild cognitive impairment screening technology.
- Kangwon National University HospitalkeyClinical trial site for aMCI EEG biomarker validation as part of the confirmatory clinical study for iSyncBrain-M1 KFDA registration.
- Hallym University Chuncheon Sacred Heart HospitalminorAcademic collaboration for brain health research and clinical applications using QEEG analysis technology.
- Hanyang University Seoul HospitalminorResearch partnership for developing QEEG-based biomarkers and digital therapeutics for neurological disorders.
- Dong-A University LINC+ & Busan Metropolitan Dementia CenterkeyCollaboration on dementia research and brain health analysis. Partnership combining Dong-A University's academic resources with Busan's metropolitan dementia care infrastructure.
- Ewha Womans University Seoul HospitalminorAcademic collaboration for QEEG research in neurological and psychiatric conditions.
- Seoul University of Buddhism Neuroscience Research InstituteminorAcademic partnership for neuroscience research combining Buddhist medicine perspectives with QEEG-based brain analysis technology.
- Yonsei University Health System (Severance Hospital)keyResearch collaboration for developing QEEG biomarkers for Lewy body dementia, depression, and other psychiatric conditions. Wide-ranging clinical research partnership.
- University of Ulsan Asan Medical CenterkeyClinical research collaboration for developing and validating digital biomarkers for various brain diseases using iSyncBrain QEEG analysis platform.
- CHA University Bundang Medical CenterkeyRehabilitation medicine research collaboration for developing QEEG-guided digital therapeutics, particularly for cerebral palsy and rehabilitation applications.
- Korea University Ansan HospitalminorResearch collaboration for Parkinson's disease studies and QEEG biomarker development.
- Inha University HospitalminorAcademic collaboration for QEEG research in neurological conditions and digital biomarker development.
- Soon Chun Hyang University Hospital BucheonminorPediatric research collaboration for developing EEG-based biomarkers for attention and developmental disorders in children.
- Dongguk University Ilsan HospitalminorAcademic collaboration for QEEG research targeting PTSD, addiction, and related psychiatric conditions.
- Ajou University HospitalminorResearch collaboration for developing QEEG biomarkers for cognitive impairment and MCI.
- Bobath Memorial HospitalminorCollaboration for neurorehabilitation research and QEEG applications in brain injury rehabilitation.
- Dong-A University / Busan Metropolitan Dementia Center MOU GroupkeyMOU for 'smart healthcare service topic discovery based on consumer data'. Collaboration between Dong-A University's LINC+ program, Busan Metropolitan Dementia Center, and iMediSync for data-driven dementia care services.
- Myungra Co., Ltd (명라)minorDiscussion meeting for activating remote healthcare services with Dubai local medical institutions. Myungra Co. and iMediSync met with Dubai medical institution representatives including Dr. Kyungsang Oh to explore telemedicine and brainwave diagnostic technology deployment in the Middle East market.
Scale indicators6 records
Recent moves8 records
Expansion highlights8 records
iMediSync competitors and assessment
Company assessmentDirect peers
- BrainScope: US-based company developing FDA-cleared EEG-based AI assessments for concussion and brain injury. Comparable to iMediSync as an EEG hardware + cloud-AI biomarker company pursuing FDA clearances for clinical brain injury and neurological condition triage in hospital and potentially consumer settings.
- Emotiv: US/Australia-based EEG hardware and software company offering consumer and research-grade dry-electrode headsets with cloud-based brain data analytics. Comparable to iMediSync on the dry-electrode EEG hardware + cloud analytics product architecture, though focused more on consumer/research than clinical.
- Ceribell: US-based point-of-care EEG company with FDA-cleared rapid brain monitoring and AI-assisted seizure detection. Comparable to iMediSync as a clinical AI-EEG platform with FDA-cleared hardware and software targeting hospital neurology decision-making, though focused on acute care rather than dementia screening.
- Cumulus Neuroscience: Ireland/UK-based company building a multi-domain EEG and digital biomarker platform for CNS clinical trials and patient monitoring. Comparable to iMediSync's iSyncBrain-R research series and biomarker development for depression, MCI, and related neurological indications.
- Wave Neuroscience: US-based company offering EEG-guided neuromodulation therapies for brain health conditions including TBI and cognitive decline. Direct peer because of the QEEG-guided treatment paradigm, including use of photobiomodulation-style stimulation, mirroring iMediSync's iSyncWave diagnostic-plus-therapy model.
- Compumedics: Australia-based manufacturer of clinical EEG, sleep diagnostics, and neurology devices. Directly comparable to iMediSync as a hardware + software neurodiagnostic platform selling to hospitals and sleep/neurology clinics globally, with overlapping customer segments in neurology and brain health assessment.
- Neuroelectrics: Spain-based company combining dry/multichannel EEG with transcranial current stimulation (tDCS/tACS) for clinical and research neuromodulation. Directly comparable to iMediSync in integrating EEG measurement with non-invasive brain stimulation therapies and offering cloud-based analysis.
Emerging players
- Neurable: US-based neurotechnology company building EEG-enabled wearable devices and brain-computer interface software for productivity, wellness, and clinical applications. Comparable as an emerging EEG wearable and analytics peer, with overlap in consumer/wellness brain health use cases adjacent to iMediSync's iSyncMe.
- Dreem: France-based neurotechnology company with a consumer EEG headband for sleep and cognitive monitoring, plus a clinical research arm developing EEG biomarkers. Comparable to iMediSync on dry EEG + cloud biomarker platform strategy, though primarily consumer/sleep-oriented rather than dementia.
Broad incumbents
- Natus Medical: US-listed incumbent in neurodiagnostic, EEG, and newborn screening equipment. Comparable as a broad EEG/neurology hardware incumbent selling to hospitals worldwide, though its portfolio spans many adjacent device categories beyond iMediSync's brain health focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
iMediSync social profiles
Digital presenceiMediSync compliance and trust
Trust signalCompliance4 records
iMediSync financial estimates
Financial estimateRevenue estimate
Valuation estimate
iMediSync leadership team
Management profileNumber of profiles
Profiles2 records
iMediSync subsidiaries and ownership
Company hierarchySubsidiaries1 record
iMediSync funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iMediSync M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iMediSync
What does iMediSync do?
iMediSync develops and sells wireless dry-electrode EEG headsets (iSyncWave and iSyncMe) integrated with near-infrared photobiomodulation (PBM) therapy, connected to a cloud-based AI analytics platform (iSyncBrain for QEEG analysis, iSyncHeart for HRV analysis). The platform performs automated brain health screening, age- and sex-normed comparison, and AI-based disease biomarker detection for conditions such as Alzheimer's, amnestic mild cognitive impairment, Parkinson's, depression, and stroke cognitive impairment. The offering is sold as regulated medical device hardware plus SaaS analytics subscriptions to hospitals, clinics, government health programs, and wellness/senior care operators.
Is iMediSync a public or private company?
iMediSync is a private company. It is classified as venture growth investor backed and is currently operating.
When was iMediSync founded?
iMediSync was founded in 2012. It employs 51 to 100 people.
Where is iMediSync based?
iMediSync is headquartered in Yeoksamdong, South Korea, in the Asia region.
How does iMediSync make money?
Four revenue lines are on record. Hardware Device Sales (iSyncWave, iSyncMe) is the primary driver. The others are cloud-Based AI Analytics Platform (iSyncBrain, iSyncHeart), software Medical Device Licensing and professional Services and Training.
Who are iMediSync's main competitors?
Direct peers on record are BrainScope, Emotiv, Ceribell, Cumulus Neuroscience, Wave Neuroscience, Compumedics and Neuroelectrics. Emerging players are Neurable and Dreem. Natus Medical is listed as a broad incumbent.
Does iMediSync have an API?
No public API is recorded for iMediSync.
What industry is iMediSync in?
iMediSync's product category is Digital Mental Health Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAPAD, Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension). Its NAICS code is 334510 and its SIC code is 3845.